{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy",
    "geneContextQualifier": "BCR | ABL1",
    "objectTherapeutic": "Nilotinib [Tasigna]"
}